Skip to main content
Premium Trial:

Request an Annual Quote

Pharma Capitalizes on Cancer Genetics

Pharmaceutical companies are starting to design clinical trials for cancer treatments using data on cancer genetics to pinpoint which patients are more likely to respond to each drug, according to MIT's Technology Review. Emily Singer writes that doctors are hoping to be able to treat patients with specific drugs according to the genetic profile of their illness, and which mutations are affecting their individual tumors. Researchers at the Wellcome Trust Sanger Institute's Cancer Genome Project are collaborating with researchers at Massachusetts General Hospital to screen 400 compounds on 1,000 cancer cell lines derived from various tumors, Singer says. "Collectively, the cells possess about 70 cancer-linked genetic mutations, about 50 to 80 percent of the mutations that have been uncovered to date," she adds.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.